Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc has developed a proprietary PREDATOR platform that enables the creation of conditionally activated molecules, designed to selectively stimulate the immune system within the tumor microenvironment, thus enhancing both safety and efficacy in cancer treatments. The positive clinical results from its lead asset WTX-124, which has demonstrated promising tolerability and anti-tumor activity in solid tumors, alongside favorable outcomes from WTX-330 and other INDUKINE programs, signal a de-risked development pathway for the company's future oncology and immune-mediated therapies. Additionally, the capacity of Werewolf's therapy to mitigate systemic toxicity while delivering significantly greater doses than traditional therapies reinforces the positive outlook, indicating potential for greater market acceptance and expansion into new therapeutic areas.

Bears say

Werewolf Therapeutics Inc. reported a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, which is notably higher than the $12.0 million loss recorded in the same quarter of the previous year. The company faces considerable risks regarding its WTX-124 program, as potential clinical or regulatory setbacks could hinder its progress and affect revenue estimates if the treatment is approved. Additionally, concerns regarding the safety, efficacy, and pharmacokinetic properties of WTX-124, along with potential competition from existing and emerging therapies, contribute to a negative outlook on the company's financial prospects.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.